Glaxo Settles Cancer Treatment IP Skirmish With Genentech
The dispute concerned U.S. Patents No. 6,331,415 and 7,923,221, the "Cabilly patents," which relate to recombinant antibody production for ofatumumab, which also goes by the GSK brand name Arzerra. GSK is Dutch biotech company Genmab's development and commercial collaborator for ofatumumab, according to Genmab.
A Genentech spokeswoman, Robin Snyder, said Genentech was satisfied with the...
To view the full article, register now.